{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,14]],"date-time":"2026-02-14T04:17:41Z","timestamp":1771042661506,"version":"3.50.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2008,5,1]],"date-time":"2008-05-01T00:00:00Z","timestamp":1209600000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,11,30]],"date-time":"2014-11-30T00:00:00Z","timestamp":1417305600000},"content-version":"vor","delay-in-days":2404,"URL":"https:\/\/www.elsevier.com\/open-access\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Microbiology and Infection"],"published-print":{"date-parts":[[2008,5]]},"DOI":"10.1111\/j.1469-0691.2008.01982.x","type":"journal-article","created":{"date-parts":[[2008,4,22]],"date-time":"2008-04-22T15:25:42Z","timestamp":1208877942000},"page":"55-64","source":"Crossref","is-referenced-by-count":26,"special_numbering":"S4","title":["New dosing strategies for liposomal amphotericin B in high-risk patients"],"prefix":"10.1016","volume":"14","author":[{"given":"Michael","family":"Ellis","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1111\/j.1469-0691.2008.01982.x_bib1","doi-asserted-by":"crossref","first-page":"1391","DOI":"10.1056\/NEJMoa040446","article-title":"Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia","volume":"351","author":"Walsh","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib2","doi-asserted-by":"crossref","first-page":"S117","DOI":"10.1086\/367839","article-title":"Forum report: issues in clinical trials of empirical antifungal therapy in treating febrile neutropenic patients","volume":"36","author":"Bennett","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib3","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib4","doi-asserted-by":"crossref","first-page":"686","DOI":"10.1086\/319211","article-title":"Mortality and costs of acute renal failure associated with amphotericin B therapy","volume":"32","author":"Bates","year":"2001","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib5","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1086\/376634","article-title":"Amphotericin B: time for a new \u2018gold standard\u2019","volume":"37","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib6","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1086\/317451","article-title":"A randomized, double-blind comparative trial evaluating the safety of liposomal amphotericin B versus amphotericin B lipid complex in the empirical treatment of febrile neutropenia. L Amph\/ABLC Collaborative Study Group","volume":"31","author":"Wingard","year":"2000","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib7","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0002-9343(82)90594-0","article-title":"Empiric antibiotic and antifungal therapy for cancer patients with prolonged fever and granulocytopenia","volume":"72","author":"Pizzo","year":"1982","journal-title":"Am J Med"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib8","doi-asserted-by":"crossref","first-page":"668","DOI":"10.1016\/0002-9343(89)90441-5","article-title":"Empiric antifungal therapy in febrile granulocytopenic patients","volume":"86","author":"EORTC International Antimicrobial Therapy Cooperative Group","year":"1989","journal-title":"Am J Med"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib9","doi-asserted-by":"crossref","first-page":"1251","DOI":"10.1086\/496933","article-title":"Between over- and undertreatment of invasive fungal disease","volume":"41","author":"de Pauw","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib10","doi-asserted-by":"crossref","first-page":"1417","DOI":"10.1086\/503427","article-title":"Diagnosis of invasive aspergillosis using a galactomannan assay: a meta-analysis","volume":"42","author":"Pfeiffer","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib11","doi-asserted-by":"crossref","first-page":"1428","DOI":"10.1086\/503432","article-title":"Galactomannan and the diagnosis of invasive aspergillosis","volume":"42","author":"Rex","year":"2006","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib12","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1086\/496927","article-title":"Galactomannan and computed tomography-based preemptive antifungal therapy in neutropenic patients at high risk for invasive fungal infection: a prospective feasibility study","volume":"41","author":"Maertens","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib13","doi-asserted-by":"crossref","first-page":"654","DOI":"10.1086\/432470","article-title":"Multicenter clinical evaluation of the (1\u20133) beta-D-glucan assay as an aid to diagnosis of fungal infections in humans","volume":"41","author":"Ostrosky-Zeichner","year":"2005","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib14","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1086\/421944","article-title":"Beta-D-glucan as a diagnostic adjunct for invasive fungal infections: validation, cutoff development, and performance in patients with acute myelogenous leukemia and myelodysplastic syndrome","volume":"39","author":"Odabasi","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib15","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1034\/j.1600-0455.2002.430310.x","article-title":"Early chest radiography and CT in the diagnosis, management and outcome of invasive pulmonary aspergillosis","volume":"43","author":"Hauggaard","year":"2002","journal-title":"Acta Radiol"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib16","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08982109309150729","article-title":"Development, characterization, efficacy and mode of action of AmBisome, a unilamellar formulation of amphotericin B","volume":"3","author":"Adler-Moore","year":"1993","journal-title":"J Liposome Res"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib17","doi-asserted-by":"crossref","first-page":"1126","DOI":"10.1093\/clinids\/23.5.1126","article-title":"Characteristics of lipid-based formulations that influence their biological behavior in the plasma of patients","volume":"23","author":"Wasan","year":"1996","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib18","first-page":"S3","article-title":"AmBisome targeting to fungal infections","volume":"14","author":"Adler-Moore","year":"1994","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib19","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib20","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1128\/AAC.49.12.4895-4902.2005","article-title":"Treatment of Candida glabrata infection in immunosuppressed mice by using a combination of liposomal amphotericin B with caspofungin or micafungin","volume":"49","author":"Olson","year":"2005","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib21","doi-asserted-by":"crossref","first-page":"2122","DOI":"10.1128\/AAC.00315-06","article-title":"Comparative efficacies, toxicities, and tissue concentrations of amphotericin B lipid formulations in a murine pulmonary aspergillosis model","volume":"50","author":"Olson","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib22","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1128\/AAC.50.2.469-473.2006","article-title":"Pharmacodynamic activity of amphotericin B deoxycholate is associated with peak plasma concentrations in a neutropenic murine model of invasive pulmonary aspergillosis","volume":"50","author":"Wiederhold","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib23","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1128\/AAC.50.2.674-684.2006","article-title":"Pharmacokinetic\u2013pharmacodynamic comparison of amphotericin B (AMB) and two lipid-associated AMB preparations, liposomal AMB and AMB lipid complex, in murine candidiasis models","volume":"50","author":"Andes","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib24","doi-asserted-by":"crossref","first-page":"1289","DOI":"10.1086\/514341","article-title":"Liposomal amphotericin B as initial therapy for invasive mold infection: a randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial)","volume":"44","author":"Comely","year":"2007","journal-title":"Clin Infect Dis"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib25","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1093\/jac\/dkm077","article-title":"Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B","volume":"59","author":"Smith","year":"2007","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib26","doi-asserted-by":"crossref","first-page":"1153","DOI":"10.1093\/jac\/dkl141","article-title":"Amphotericin B tissue distribution in autopsy material after treatment with liposomal amphotericin B and amphotericin B colloidal dispersion","volume":"57","author":"Vogelsinger","year":"2006","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib27","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1179\/joc.2005.17.1.82","article-title":"Penetration of amphotericin B in human lung tissue after single liposomal amphotericin B (AmBisome) infusion","volume":"17","author":"Demartini","year":"2005","journal-title":"J Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib28","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1093\/jac\/28.suppl_B.73","article-title":"Efficacy of amphotericin B encapsulated in liposomes (AmBisome) in the treatment of invasive fungal infections in immunocompromised patients","volume":"28","author":"Ringd\u00e9n","year":"1991","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib29","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1128\/AAC.33.3.362","article-title":"Tissue concentrations and bioactivity of amphotericin B in cancer patients treated with amphotericin B-deoxycholate","volume":"33","author":"Collette","year":"1989","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib30","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1128\/AAC.40.5.1214","article-title":"Therapy of visceral leishmaniasis due to Leishmania infantum: experimental assessment of efficacy of AmBisome","volume":"40","author":"Gangneux","year":"1996","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib31","doi-asserted-by":"crossref","first-page":"3418","DOI":"10.1128\/AAC.00241-06","article-title":"Compartmentalized intrapulmonary pharmacokinetics of amphotericin B and its lipid formulations","volume":"50","author":"Groll","year":"2006","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib32","first-page":"179","article-title":"Effect of tissue penetration on AmBisome efficacy","volume":"4","author":"Adler-Moore","year":"2003","journal-title":"Curr Opin Investig Drugs"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib33","doi-asserted-by":"crossref","first-page":"2327","DOI":"10.1128\/AAC.44.9.2327-2332.2000","article-title":"Single-dose AmBisome (liposomal amphotericin B) as prophylaxis for murine systemic candidiasis and histoplasmosis","volume":"44","author":"Garcia","year":"2000","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib34","doi-asserted-by":"crossref","first-page":"1096","DOI":"10.1093\/jac\/dkh460","article-title":"Alternative dosing regimens of liposomal amphotericin B (AmBisome) effective in treating murine systemic candidiasis","volume":"54","author":"Adler-Moore","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib35","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/sj.bmt.1705592","article-title":"High-dose weekly liposomal amphotericin B antifungal prophylaxis following reduced-intensity conditioning allogeneic stem cell transplantation","volume":"39","author":"El-Cheikh","year":"2007","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib36","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/j.bbmt.2005.10.010","article-title":"High-dose weekly AmBisome antifungal prophylaxis in pediatric patients undergoing hematopoietic stem cell transplantation: a pharmacokinetic study","volume":"12","author":"Mehta","year":"2006","journal-title":"Biol Blood Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib37","article-title":"Safety of a weekly administration of 10 mg\/kg of liposomal amphotericin B for antifungal prophylaxis in allogeneic stem-cell transplant and acute leukemia patients","volume":"106","author":"Cordonnier","year":"2005","journal-title":"Blood"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib38","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/sj.bmt.1701543","article-title":"Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double-blind, placebo-controlled study","volume":"23","author":"Kelsey","year":"1999","journal-title":"Bone Marrow Transplant"},{"key":"10.1111\/j.1469-0691.2008.01982.x_bib39","doi-asserted-by":"crossref","first-page":"1306","DOI":"10.1093\/annonc\/mdl128","article-title":"Low-dose liposomal amphotericin B in the prevention of invasive fungal infections in patients with prolonged neutropenia: results from a randomized, single-center trial","volume":"17","author":"Penack","year":"2006","journal-title":"Ann Oncol"}],"container-title":["Clinical Microbiology and Infection"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14616177?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1198743X14616177?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2019,5,10]],"date-time":"2019-05-10T12:26:35Z","timestamp":1557491195000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1198743X14616177"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,5]]},"references-count":39,"alternative-id":["S1198743X14616177"],"URL":"https:\/\/doi.org\/10.1111\/j.1469-0691.2008.01982.x","relation":{},"ISSN":["1198-743X"],"issn-type":[{"value":"1198-743X","type":"print"}],"subject":[],"published":{"date-parts":[[2008,5]]}}}